Prostate Cancer - Results from #23780

Castrate-resistant prostate cancer: Postdocetaxel management - Abstract February 22, 2013

Dynamic PET/CT measurements of induced positron activity in a prostate cancer patient after 50-MV photon radiation therapy - Abstract February 22, 2013

GU Cancers Symposium 2013 - Serum IGF-1 levels are decreased in men with advanced prostate cancer treated with the ERα agonist, GTx-758, by Evan Y. Yu, MD, et al. - Poster February 22, 2013

Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer - Abstract February 22, 2013

Impact of bent distortion on accuracy of measurement during transrectal ultrasonography for prostatic imaging: A preliminary study - Abstract February 22, 2013

Risk of suicide in men with low-risk prostate cancer - Abstract February 22, 2013

Prostate cancer disease severity and country of origin among black men in the United States - Abstract February 22, 2013

GU Cancers Symposium 2013 - Variations in treatment modality use for the definitive management of prostate cancer in the United States, by Jay P. Ciezki, MD , et al. - Poster February 22, 2013

GU Cancers Symposium 2013 - Variations in treatment modality use for the definitive management of prostate cancer in the United States, by Jay P. Ciezki, MD , et al. - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Stereotactic body radiation (SBRT) following procedures for benign prostatic hyperplasia (BPH): A report of early toxicity, by Marie Kate Gurka, MD, et al. - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) - Session Highlights February 21, 2013

Racial disparities in survival after diagnosis of prostate cancer in Kentucky, 2001-2010 - Abstract February 21, 2013

Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer - Abstract February 21, 2013

Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer - Abstract February 21, 2013

Enzalutamide, a second generation androgen receptor antagonist: Development and clinical applications in prostate cancer - Abstract February 21, 2013

GU Cancers Symposium 2013 - Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase 3 study of abiraterone acetate in metastatic castration-resistant prostate cancer, by Oscar B. Goodman Jr., MD, PhD, et al. - Poster February 21, 2013

Bone metastases from prostate cancer: 18F-fluoride PET/CT in a patient with discordant bone scintigraphy and 11C-choline PET/CT - Abstract February 21, 2013

Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: Results of a multi-institutional phase II trial - Abstract February 21, 2013

Spacer stability and prostate position variability during radiotherapy for prostate cancer applying a hydrogel to protect the rectal wall - Abstract February 21, 2013

Cost of prostate image-guided radiation therapy: Results of a randomized trial - Abstract February 21, 2013

Page 1190 of 1436